Back to top

pharmaceuticals: Archive

Zacks Equity Research

Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win

LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.

PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change

Ahan Chakraborty

NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?

Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.

NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change

Zacks Equity Research

Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?

BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.

RHHBYNo Net Change BMYPositive Net Change MRKPositive Net Change

Zacks Equity Research

Kymera's Eczema Drug Gets Fast Track Designation in the United States

KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.

SNYNegative Net Change GILDNegative Net Change KYMRPositive Net Change

Kanishka Das

Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?

Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.

AZNNegative Net Change RHHBYNo Net Change BMYPositive Net Change MRKPositive Net Change

Sundeep Ganoria

Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis

AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.

JNJPositive Net Change AMGNNegative Net Change ARGXNegative Net Change

Kinjel Shah

AbbVie Slipped Below 50-Day SMA Last Week: How to Play the Stock

AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.

AZNNegative Net Change JNJPositive Net Change LLYPositive Net Change ABBVNegative Net Change

Shaun Pruitt

Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank

Adding to the unusually strong performance of the Russell 2000 this year, these top performers may certainly serve as stocks to add to your watchlist

BETRNegative Net Change COGTPositive Net Change CELCPositive Net Change RGCPositive Net Change OPENNegative Net Change IWMNegative Net Change

Zacks Equity Research

Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III

RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.

RHHBYNo Net Change LLYPositive Net Change ANIPNegative Net Change CRMDPositive Net Change

Ahan Chakraborty

Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in the development of their GLP-1 therapies.

NVOPositive Net Change LLYPositive Net Change GPCRPositive Net Change

Zacks Equity Research

WVE Stock Surges More Than 180% in a Week: What Is Driving This Rally?

Wave Life Sciences' shares jump 183% as early INLIGHT data on weight-loss drug WVE-007 show notable visceral fat cuts and gains in lean mass.

NVOPositive Net Change LLYPositive Net Change WVENegative Net Change

Kinjel Shah

GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?

GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.

AZNNegative Net Change GSKNegative Net Change NVOPositive Net Change LLYPositive Net Change

Sundeep Ganoria

Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth

ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.

AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change ABBVNegative Net Change

Mark Vickery

Top Research Reports for Broadcom, Exxon Mobil & Johnson & Johnson

Broadcom rides surging AI semiconductor demand and VMware integration strength, even as margins tighten and debt remains a drag.

JNJPositive Net Change XOMNegative Net Change TRMBNegative Net Change AVGONegative Net Change SYFNegative Net Change ITICPositive Net Change APTVNegative Net Change FRDPositive Net Change

Ahan Chakraborty

Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?

Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.

NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change

Kinjel Shah

PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence

Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.

PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change

Kinjel Shah

JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?

JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.

JNJPositive Net Change PFEPositive Net Change

Aparajita Dutta

Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal

Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.

BMYPositive Net Change JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change ABBVNegative Net Change PJPPositive Net Change IHEPositive Net Change PPHPositive Net Change

Kinjel Shah

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play

Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.

SNYNegative Net Change BMYPositive Net Change NVOPositive Net Change TEVANegative Net Change

Kinjel Shah

MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?

Merck holds bullish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.

MRKPositive Net Change MRNAPositive Net Change CDTXPositive Net Change SMMTNegative Net Change

Zacks Equity Research

GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron

Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across multiple studies.

NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change

Sanghamitra Saha

Pharma ETF (XPH) Hits a New 52-Week High

Pharma ETF XPH hits a fresh 52-week high as healthcare shines amid AI bubble fears and slowing growth. Biotech M&A adds fuel -- can momentum hold?

XPHNo Net Change

Zacks Equity Research

Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's

Sandoz, Teva and Dr. Reddy's emerge as standouts as generic drugmakers lean on biosimilars, complex generics and tighter cost controls.

RDYNegative Net Change TEVANegative Net Change SDZNYNegative Net Change

Ekta Bagri

Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?

Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.

BIIBPositive Net Change BMYPositive Net Change LLYPositive Net Change

Kinjel Shah

Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?

J&J faces Stelara losses, Medicare shifts, talc suits and China pressure, banking on new products and expects segment growth to stay on track.

JNJPositive Net Change AMGNNegative Net Change TEVANegative Net Change